News Conference News AHA 2024 SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity Michael O'Riordan November 16, 2024
News Conference News THT 2024 Debating the Role of T-TEER in the Sickest Patients Michael O'Riordan March 05, 2024
News Daily News Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse Todd Neale January 21, 2022
News Features Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle Shelley Wood October 08, 2021
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021
News Conference News TVT 2021 Optimizing Medical Therapy Before Clip Repair for MR? ‘This Is Hard’ Todd Neale July 27, 2021
News Daily News Echo Features Pinpoint Those Unlikely to Benefit From MitraClip Shelley Wood December 15, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Daily News RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators L.A. McKeown August 21, 2019
News Daily News Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy Shelley Wood May 09, 2019
News Features Mercury Rising: As Doctors’ Groups Face Off Over BP Guidelines, Will Patients Fall Through the Cracks? L.A. McKeown February 26, 2018
News Conference News AHA 2016 No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION Shelley Wood November 13, 2016
News Conference News AHA 2016 Early Vasodilator Therapy Not the Answer for Improving Long-term Outcomes After Acute Decompensated Heart Failure Todd Neale November 13, 2016
News Daily News Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV Michael O'Riordan December 15, 2015
News Daily News Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee Michael O'Riordan December 15, 2015
News Industry News Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure December 10, 2015
News Industry News Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan) July 07, 2015